Analyst Reco. EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

PV3B

US30233G2093

Real-time Estimate Tradegate Other stock markets 02:52:25 2024-07-11 pm EDT			5-day change	1st Jan Change
8.756 ^EUR	+8.37%		+0.20%	-62.69%

Jun. 26	EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024	CI
Jun. 26	Transcript : EyePoint Pharmaceuticals, Inc. - Special Call

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating	Jun. 04	MT
Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating	May. 08	MT
Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating	May. 07	MT
Mizuho Securities Cuts Price Target on EyePoint Pharmaceuticals to $30 From $39, Maintains Buy Rating	May. 07	MT
Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating	Feb. 15	MT
JPMorgan Starts EyePoint Pharmaceuticals With Overweight Rating, $35 Price Target	Jan. 22	MT
Capital One Starts Coverage on EyePoint Pharmaceuticals with Overweight Rating, $44 Price Target	Dec. 11	MT
Mizuho Ups Price Target on EyePoint Pharmaceuticals to $30 From $20, Citing 'Resoundingly Positive' Data for Lead Asset EYP-1901, Reiterates Buy Rating	Dec. 07	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $25 From $27, Keeps Buy Rating	Nov. 02	MT
Mizuho Initiates EyePoint Pharmaceuticals With Buy Rating, Price Target is $20	Nov. 02	MT
JonesTrading Initiates EyePoint Pharmaceuticals at Buy With $26 Price Target	23-06-14	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $27 From $25, Keeps Buy Rating	23-05-19	MT
Chardan Raises Price Target on EyePoint Pharmaceuticals to $22 From $21, Keeps Buy Rating	23-05-19	MT
Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $52 From $60, Maintains Buy Rating	22-11-11	MT
HC Wainwright Lifts Price Target on EyePoint Pharmaceuticals to $25 From $24, Reiterates Buy Rating	22-08-04	MT
Chardan Capital Initiates EyePoint Pharmaceuticals at Buy with $21 Price Target	22-07-07	MT
Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $75 From $22, Maintains Buy Rating	21-11-15	MT
Cowen Adjusts Price Target on EyePoint Pharmaceuticals to $35 From $25, Keeps Outperform Rating	21-11-15	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $24 From $15, Keeps Buy Rating	21-11-15	MT
EYEPOINT PHARMACEUTICALS : HC Wainwright Adjusts EyePoint Pharmaceuticals' Price Target to $15 From $16, Maintains Buy Rating	21-05-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

PV3B

US30233G2093

Analyst Reco.

Filters